CryoPort (CYRX)
(Delayed Data from NSDQ)
$13.66 USD
-0.39 (-2.78%)
Updated May 16, 2024 04:00 PM ET
After-Market: $13.63 -0.03 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
CryoPort, Inc. [CYRX]
Reports for Purchase
Showing records 21 - 40 ( 192 total )
Company: CryoPort, Inc.
Industry: Transportation - Services
Cryoport Lowers Guidance: Implications for CGT Players
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Dizzying See-Saw of Expectations Continues; PT Cut to $25.00
Provider: Roth Capital Partners, Inc.
Analyst: BALDRY R
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
1Q23 Growth Acceleration Underpins Strong 2023 Growth Guidance
Provider: Roth Capital Partners, Inc.
Analyst: BALDRY R
Company: CryoPort, Inc.
Industry: Transportation - Services
1Q23 Counters Investor Skepticism About Cell Gene Therapy
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
2023 KBCM Life Sciences & MedTech Forum: Day 2 Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Risk Factors for Life Science May Be de Minimis
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
4Q22 Exceeds with Encouraging Cell & Gene Therapy Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Healthcare: Life Sciences Tools & Services
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
MVE Uncertainty but FY23-25 Shows Exponential Cell Therapy Potential`
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
Company: CryoPort, Inc.
Industry: Transportation - Services
3Q22 - Macro Drives Miss but Phase III CGT Programs Reach 80
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department